450 related articles for article (PubMed ID: 28057743)
1.
Bolzoni M; Ronchetti D; Storti P; Donofrio G; Marchica V; Costa F; Agnelli L; Toscani D; Vescovini R; Todoerti K; Bonomini S; Sammarelli G; Vecchi A; Guasco D; Accardi F; Palma BD; Gamberi B; Ferrari C; Neri A; Aversa F; Giuliani N
Haematologica; 2017 Apr; 102(4):773-784. PubMed ID: 28057743
[TBL] [Abstract][Full Text] [Related]
2. CD14+ CD16+ monocytes rather than CD14+ CD51/61+ monocytes are a potential cytological marker of circulating osteoclast precursors in multiple myeloma. A preliminary study.
Petitprez V; Royer B; Desoutter J; Guiheneuf E; Rigolle A; Marolleau JP; Kamel S; Guillaume N
Int J Lab Hematol; 2015 Feb; 37(1):29-35. PubMed ID: 24661393
[TBL] [Abstract][Full Text] [Related]
3. PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients.
Costa F; Vescovini R; Marchica V; Storti P; Notarfranchi L; Dalla Palma B; Toscani D; Burroughs-Garcia J; Catarozzo MT; Sammarelli G; Giuliani N
Front Immunol; 2020; 11():613007. PubMed ID: 33488620
[TBL] [Abstract][Full Text] [Related]
4. Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation.
Giuliani N; Ferretti M; Bolzoni M; Storti P; Lazzaretti M; Dalla Palma B; Bonomini S; Martella E; Agnelli L; Neri A; Ceccarelli F; Palumbo C
Leukemia; 2012 Jun; 26(6):1391-401. PubMed ID: 22289923
[TBL] [Abstract][Full Text] [Related]
5. Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma.
Manier S; Kawano Y; Bianchi G; Roccaro AM; Ghobrial IM
Curr Opin Hematol; 2016 Jul; 23(4):426-33. PubMed ID: 27101529
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance.
Skrtić A; Korać P; Krišto DR; Ajduković Stojisavljević R; Ivanković D; Dominis M
Hum Pathol; 2010 Dec; 41(12):1702-10. PubMed ID: 20800871
[TBL] [Abstract][Full Text] [Related]
7. CD229 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma and Monoclonal Gammopathies of Uncertain Significance.
Carulli G; Buda G; Azzarà A; Ciancia EM; Sammuri P; Domenichini C; Guerri V; Petrini M
Acta Haematol; 2016; 135(1):11-4. PubMed ID: 26303094
[No Abstract] [Full Text] [Related]
8. Characterization of the CD14++CD16+ monocyte population in human bone marrow.
Mandl M; Schmitz S; Weber C; Hristov M
PLoS One; 2014; 9(11):e112140. PubMed ID: 25369328
[TBL] [Abstract][Full Text] [Related]
9. Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation in vitro.
Tucci M; Ciavarella S; Strippoli S; Brunetti O; Dammacco F; Silvestris F
Exp Hematol; 2011 Jul; 39(7):773-83.e1. PubMed ID: 21569821
[TBL] [Abstract][Full Text] [Related]
10. LIGHT/TNFSF14 as a New Biomarker of Bone Disease in Multiple Myeloma Patients Experiencing Therapeutic Regimens.
Brunetti G; Rizzi R; Storlino G; Bortolotti S; Colaianni G; Sanesi L; Lippo L; Faienza MF; Mestice A; Curci P; Specchia G; Grano M; Colucci S
Front Immunol; 2018; 9():2459. PubMed ID: 30405638
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes.
Frassanito MA; Desantis V; Di Marzo L; Craparotta I; Beltrame L; Marchini S; Annese T; Visino F; Arciuli M; Saltarella I; Lamanuzzi A; Solimando AG; Nico B; De Angelis M; Racanelli V; Mariggiò MA; Chiacchio R; Pizzuti M; Gallone A; Fumarulo R; D'Incalci M; Vacca A
J Pathol; 2019 Feb; 247(2):241-253. PubMed ID: 30357841
[TBL] [Abstract][Full Text] [Related]
13. CD14
Xue J; Xu L; Zhu H; Bai M; Li X; Zhao Z; Zhong H; Cheng G; Li X; Hu F; Su Y
Arthritis Res Ther; 2020 Sep; 22(1):221. PubMed ID: 32958023
[TBL] [Abstract][Full Text] [Related]
14. Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma.
Salem DA; Korde N; Venzon DJ; Liewehr DJ; Maric I; Calvo KR; Braylan R; Tembhare PR; Yuan CM; Landgren CO; Stetler-Stevenson M
Leuk Lymphoma; 2018 Jan; 59(1):178-186. PubMed ID: 28540748
[TBL] [Abstract][Full Text] [Related]
15. Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance.
Thiago LS; Perez-Andres M; Balanzategui A; Sarasquete ME; Paiva B; Jara-Acevedo M; Barcena P; Sanchez ML; Almeida J; González M; San Miguel JF; Garcia-Sanz R; Orfao A
Haematologica; 2014 Jan; 99(1):155-62. PubMed ID: 23872308
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients.
Sarasquete ME; Gutiérrez NC; Misiewicz-Krzeminska I; Paiva B; Chillón MC; Alcoceba M; García-Sanz R; Hernández JM; González M; San-Miguel JF
Haematologica; 2011 Mar; 96(3):468-71. PubMed ID: 21160068
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression.
Liu Z; Xu J; Li H; Zheng Y; He J; Liu H; Zhong Y; Lu Y; Hong B; Zhang M; Lin P; Du J; Hou J; Qian J; Kwak LW; Yi Q; Yang J
PLoS One; 2013; 8(12):e82453. PubMed ID: 24340030
[TBL] [Abstract][Full Text] [Related]
18. CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features.
Schmidt-Hieber M; Pérez-Andrés M; Paiva B; Flores-Montero J; Perez JJ; Gutierrez NC; Vidriales MB; Matarraz S; San Miguel JF; Orfao A
Haematologica; 2011 Feb; 96(2):328-32. PubMed ID: 20971816
[TBL] [Abstract][Full Text] [Related]
19. Combined TRAF6 Targeting and Proteasome Blockade Has Anti-myeloma and Anti-Bone Resorptive Effects.
Chen H; Li M; Sanchez E; Wang CS; Lee T; Soof CM; Casas CE; Cao J; Xie C; Udd KA; DeCorso K; Tang GY; Spektor TM; Berenson JR
Mol Cancer Res; 2017 May; 15(5):598-609. PubMed ID: 28122920
[TBL] [Abstract][Full Text] [Related]
20. CD14
Storti P; Vescovini R; Costa F; Marchica V; Toscani D; Dalla Palma B; Craviotto L; Malavasi F; Giuliani N
Br J Haematol; 2020 Aug; 190(3):430-436. PubMed ID: 32162328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
